Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2014

01.06.2014 | Original Article

Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?

verfasst von: Harrison X. Bai, Sabin B. Motwani, Susan A. Higgins, Bruce G. Haffty, Lynn D. Wilson, Donald R. Lannin, Suzanne B. Evans, Meena S. Moran

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

For DCIS patients eligible for breast conservation treatment (BCT), it remains unclear whether presenting with physical signs/symptoms (Phys) confers a worse long-term prognosis compared to mammographically detected DCIS (Mam).

Methods

We collected data on 669 DCIS patients treated with BCT from 1974 to 2007 of whom 80 were identified as category “Phys” and 589 were in category “Mam.”

Results

Treatment parameters (i.e., the RT dose delivered, boost, rates of stereotactic biopsy, re-excision, node dissection) did not differ significantly between the two cohorts (p = NS). At a 60-month median follow-up, significant associations included younger age at presentation (p < 0.001), non-white race (p = 0.041), larger tumor size (p = 0.002), more 1°/2° papillary histology (1°, p = 0.001; 2°, p = 0.005) for the Phys cohort. As expected, mammograms were more likely to show mass/nodules/asymmetrical densities and less likely to show microcalcifications for the Phys versus Mam group (p < 0.0001). There were no differences in family history, multifocality, grade, necrosis, or residual disease at re-excision, nodal involvement, status of margins, or ER/PR/HER-2 between the cohorts. The local relapse-free survival was similar at 5 years (100 vs. 96.9 %, p = 0.116) and 10 years (96.2 vs. 96.2 %, p = 0.906), with no significant overall survival difference at 10 years (97.5 vs. 95.9 %, p = 0.364) between the Phys and Mam patients, respectively. On multivariate analysis, presentation was not an independent predictor of local relapse-free survival or overall survival when accounting for age, race, tumor size, mammogram appearance, and adjuvant hormone treatment.

Conclusions

Our findings suggest that although some clinicopathological differences exist between DCIS patients presenting with physical signs/symptoms compared with those presenting with mammographically detected disease, long-term outcomes are similar for patients appropriately selected for BCT.
Literatur
1.
Zurück zum Zitat Schnitt SJ, Silen W, Sadowsky NL et al (1988) Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318:898–903PubMedCrossRef Schnitt SJ, Silen W, Sadowsky NL et al (1988) Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318:898–903PubMedCrossRef
2.
Zurück zum Zitat Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554PubMedCrossRef Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554PubMedCrossRef
3.
Zurück zum Zitat Evans AJ, Pinder SE, Ellis IO et al (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8:149–151PubMedCrossRef Evans AJ, Pinder SE, Ellis IO et al (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8:149–151PubMedCrossRef
4.
Zurück zum Zitat Bansal GJ, Thomas KG (2011) Screen-detected breast cancer: does presence of minimal signs on prior mammograms predict staging or grading of cancer? Clin Radiol 66:605–608PubMedCrossRef Bansal GJ, Thomas KG (2011) Screen-detected breast cancer: does presence of minimal signs on prior mammograms predict staging or grading of cancer? Clin Radiol 66:605–608PubMedCrossRef
5.
Zurück zum Zitat Evans AJ, Pinder S, Ellis IO et al (1994) Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 191:237–240PubMed Evans AJ, Pinder S, Ellis IO et al (1994) Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 191:237–240PubMed
6.
Zurück zum Zitat Walker RA, Dearing SJ, Brown LA (1999) Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 30:943–948PubMedCrossRef Walker RA, Dearing SJ, Brown LA (1999) Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 30:943–948PubMedCrossRef
7.
Zurück zum Zitat Bellamy CO, McDonald C, Salter DM et al (1993) Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 24:16–23PubMedCrossRef Bellamy CO, McDonald C, Salter DM et al (1993) Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 24:16–23PubMedCrossRef
8.
Zurück zum Zitat Pandya S, Mackarem G, Lee AK et al (1998) Ductal carcinoma in situ: the impact of screening on clinical presentation and pathologic features. Breast J 4:146–151CrossRef Pandya S, Mackarem G, Lee AK et al (1998) Ductal carcinoma in situ: the impact of screening on clinical presentation and pathologic features. Breast J 4:146–151CrossRef
9.
Zurück zum Zitat Shin HJ, Kim HH, Kim SM et al (2008) Screening-detected and symptomatic ductal carcinoma in situ: differences in the sonographic and pathologic features. AJR Am J Roentgenol 190:516–525PubMedCrossRef Shin HJ, Kim HH, Kim SM et al (2008) Screening-detected and symptomatic ductal carcinoma in situ: differences in the sonographic and pathologic features. AJR Am J Roentgenol 190:516–525PubMedCrossRef
10.
Zurück zum Zitat Idvall I, Andersson C, Fallenius G et al (2001) Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening. Acta Oncol 40:653–659PubMedCrossRef Idvall I, Andersson C, Fallenius G et al (2001) Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening. Acta Oncol 40:653–659PubMedCrossRef
11.
Zurück zum Zitat Han K, Nofech-Mozes S, Narod S et al (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 24:183–189CrossRef Han K, Nofech-Mozes S, Narod S et al (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 24:183–189CrossRef
12.
Zurück zum Zitat Rakovitch E, Nofech-Mozes S, Hanna W et al (2012) HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 106:1160–1165PubMedCentralPubMedCrossRef Rakovitch E, Nofech-Mozes S, Hanna W et al (2012) HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 106:1160–1165PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628–3636PubMedCrossRef Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628–3636PubMedCrossRef
14.
Zurück zum Zitat Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387PubMedCrossRef Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387PubMedCrossRef
15.
Zurück zum Zitat Fisher B, Land S, Mamounas E et al (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400PubMedCrossRef Fisher B, Land S, Mamounas E et al (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400PubMedCrossRef
Metadaten
Titel
Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?
verfasst von
Harrison X. Bai
Sabin B. Motwani
Susan A. Higgins
Bruce G. Haffty
Lynn D. Wilson
Donald R. Lannin
Suzanne B. Evans
Meena S. Moran
Publikationsdatum
01.06.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0575-0

Weitere Artikel der Ausgabe 3/2014

International Journal of Clinical Oncology 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.